At Sapience, our mission is clear - to create novel medicines for those suffering from difficult to treat cancers by targeting previously undruggable proteins in cancer cells. To do this, we use our library-based platform called PADS to enable discovery of new molecular entities and generate a pipeline of novel peptide drug candidates.
Many cancer drugs on the market and in development have limitations that prevent them from addressing potentially important drug targets within the cancer cell, the so-called undruggable targets. Our data suggests that our therapeutic approach, which utilizes peptides, may bypass these limitations. Our lead drug candidate and prototype, ST101, initiated a Phase 1/2 clinical trial in July 2020, in patients with advanced unresectable and metastatic solid tumors. In our pre-clinical pipeline, which spans early discovery through late stage lead selection, we have peptides that may address well regarded cancer targets, including β-catenin, Myc, cJun, FOXP3 and more.
Location: United States, New York, Harrison
Member count: 11-50
Total raised: $14M
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | Connectivi... | connectivi... |
| - | Eshelman V... | eshelmanve... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 12.07.2021 | - | $14M | - | connectivi... |
Mentions in press and media 5
| Date | Title | Description | Category | Author | Source |
| 01.12.2021 | Sapience T... | HARRISON, N.Y., Dec. 1, 2021 /... | - | - | salamancap... |
| 10.11.2021 | Sapience T... | HARRISON, N.Y., Nov. 10, 2021 ... | - | - | salamancap... |
| 13.09.2021 | Sapience T... | HARRISON, N.Y., Sept. 13, 20... | - | - | prnewswire... |
| 15.07.2021 | Sapience T... | HARRISON, N.Y., July 15, 2021 ... | - | - | salamancap... |
| 12.07.2021 | Sapience T... | Sapience Therapeutics, Inc. ,... | Fund News ... | - | connectivi... |